Tentt

MannKind Reports scPharmaceuticals Acquisition Update

Closed
HealthcareConnecticutAdd-on

Deal Overview

MannKind Corporation reported fourth-quarter and full-year 2025 financial results and provided a business update in an SEC 8-K filing. The company reported Q4 2025 revenues of $112M and full-year 2025 revenues of $349M.

MannKind also disclosed that it successfully completed its acquisition of scPharmaceuticals Inc. on October 7, 2025. The update highlights Furoscix Q4 2025 net sales of $23M and Afrezza Q4 2025 net sales of $23M, plus upcoming FDA review milestones for Furoscix ReadyFlow Autoinjector (PDUFA July 26, 2026) and Afrezza pediatric sBLA (PDUFA May 29, 2026).

Key Details

Transaction
MannKind acquires scPharmaceuticals
Deal Size
Over $100M

Source

Read full article on sec.gov

via SEC EDGAR 8-K · February 26, 2026

Related Deals